Note de episod
Send us Fan Mail ASX Investment Opportunity - Cyclopharm Ltd (ASX:CYC) China’s leading medical bodies have now named Technegas the preferred ventilation agent for pulmonary embolism imaging, and that single line has big implications. We sit down with Cyclopharm Managing Director and CEO James McBrayer to unpack what’s driving the sudden global alignment of clinical guidelines across the US, Europe, Australia and New Zealand, and China and why it’s rare for medical guidance to call out a bran...

